Repligen Corp
NASDAQ:RGEN
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
119.79
208.42
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Repligen Corp
Pre-Tax Income
Repligen Corp
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Repligen Corp
NASDAQ:RGEN
|
Pre-Tax Income
$4.9m
|
CAGR 3-Years
-67%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-11%
|
||
Thermo Fisher Scientific Inc
NYSE:TMO
|
Pre-Tax Income
$6.8B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
13%
|
||
Danaher Corp
NYSE:DHR
|
Pre-Tax Income
$4.1B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
7%
|
CAGR 10-Years
2%
|
||
Mettler-Toledo International Inc
NYSE:MTD
|
Pre-Tax Income
$955.2m
|
CAGR 3-Years
1%
|
CAGR 5-Years
7%
|
CAGR 10-Years
8%
|
||
Agilent Technologies Inc
NYSE:A
|
Pre-Tax Income
$1.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
||
IQVIA Holdings Inc
NYSE:IQV
|
Pre-Tax Income
$1.5B
|
CAGR 3-Years
17%
|
CAGR 5-Years
33%
|
CAGR 10-Years
12%
|
Repligen Corp
Glance View
Repligen Corp., a prominent player in the bioprocessing industry, has carved out a niche that centers on providing high-quality bioprocessing solutions for the production of biologics, particularly therapeutic proteins and monoclonal antibodies. Founded in 1981 and headquartered in Waltham, Massachusetts, Repligen has transformed itself from a developer of research tools into a critical partner for biopharmaceutical manufacturers. The company is primarily engaged in producing innovative products that enhance the efficiency and effectiveness of biomanufacturing processes. Its offerings range from filtration systems to cell culture media, all designed to accelerate drug development and ensure consistent product quality. Through strategic acquisitions and partnerships, Repligen has expanded its portfolio and technological capabilities, positioning itself as a leading provider in a high-demand market driven by the growing need for biologic therapies. For investors, Repligen represents a compelling opportunity rooted in its impressive growth trajectory and strong financial performance. The company has consistently reported rising revenues, bolstered by the increasing global demand for biologics and bioprocessing innovations. Repligen’s continuous investment in research and development ensures that it remains at the forefront of technological advancements, while its robust customer base includes some of the world’s leading pharmaceutical and biotech companies. With a strong balance sheet and a commitment to operational excellence, Repligen is poised for sustainable growth in an industry that is expected to expand significantly over the coming years. For those seeking exposure to the booming biopharmaceutical sector, Repligen offers a unique position that balances innovation, growth potential, and strategic leadership.
See Also
What is Repligen Corp's Pre-Tax Income?
Pre-Tax Income
4.9m
USD
Based on the financial report for Sep 30, 2024, Repligen Corp's Pre-Tax Income amounts to 4.9m USD.
What is Repligen Corp's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-11%
Over the last year, the Pre-Tax Income growth was -96%. The average annual Pre-Tax Income growth rates for Repligen Corp have been -67% over the past three years , -30% over the past five years , and -11% over the past ten years .